Trigeminal Neuralgia (TN) Treatment Market

Market Overview

The global trigeminal neuralgia (TN) treatment market size was valued at USD 243.17 million in 2023. It is estimated to reach USD 374.69 million by 2032, growing at a CAGR of 4.9% during the forecast period (2024–2032). The global trigeminal neuralgia (TN) treatment market is primarily boosted by the surging incidence of TN disease worldwide. Additionally, the surge in the geriatric population is further increasing the burden of this disease, which is anticipated to expedite the market expansion. Moreover, various initiatives to raise awareness about the disease and its possible treatment are estimated to create market expansion opportunities.

Market Overview

Trigeminal Neuralgia (TN) is a chronic pain condition affecting the trigeminal nerve, causing intense, stabbing facial pain. Treatment aims to alleviate pain and improve quality of life. Initially, medication such as anticonvulsants (e.g., carbamazepine, gabapentin) may be prescribed to manage pain. However, if medication is ineffective or intolerable, surgical interventions may be considered.

Microvascular decompression involves repositioning blood vessels compressing the trigeminal nerve, while radiosurgery (e.g., Gamma Knife) targets nerve tissue with focused radiation to alleviate pain. Other options include nerve blocks, where an anesthetic is injected to temporarily numb the affected nerve, and nerve ablation procedures that destroy nerve fibers transmitting pain signals. Treatment choice depends on factors like severity of symptoms, individual response to medications, and patient preference, often requiring a multidisciplinary approach involving neurologists, neurosurgeons, and pain management specialists.

Highlights

• North America is the highest shareholder in the global market

Market Dynamics

Global Trigeminal Neuralgia (TN) Treatment Market Drivers

Increasing Incidence of Trigeminal Neuralgia (TN)

The prevalence of Trigeminal Neuralgia (TN) directly influences the demand for treatment options. TN is a relatively rare condition, but its incidence increases, particularly as diagnostic techniques improve and awareness grows. Estimates suggest that TN affects around 4 to 13 per 100,000 people globally, with higher rates in older individuals.

The incidence of the disease was higher for females and surged with older age. Additionally, TN can significantly impact patients' quality of life, driving them to seek effective treatments. Consequently, healthcare providers and pharmaceutical companies are motivated to develop innovative therapies to address this unmet medical need, further fueling market expansion and investment in TN treatment research and development.

Growth in the Aging Population

The rising geriatric population worldwide significantly drives the Trigeminal Neuralgia (TN) treatment market. TN is more common among older persons and is expected to rise as the world's population ages. According to research titled "Incidence of trigeminal neuralgia: A population-based study in Central Sweden," published in the Wiley, the incidence of this disease increases as individuals get older, starting from 0.1 in individuals aged 0 to 19 years and reaching 23.1 per 100,000 person-years in those aged 80 years and above in Central Sweden.

Moreover, as per the United Nations, the proportion of those aged 65 years and above is growing faster than those below 65. The global population of 65 and older is predicted to surge from 10% in 2022 to 16% in 2050. Similarly, according to projections, the global population of people aged 65 years or older is expected to quadruple the number of children under five years old by 2050 and come close to matching the number of children under 12 years old. This demographic shift translates to a larger pool of potential patients requiring treatment for TN-related pain.

Global Trigeminal Neuralgia (TN) Treatment Market Restraint

Limited Understanding of Pathophysiology

The limited understanding of Trigeminal Neuralgia's (TN) pathophysiology presents a significant restraint in its treatment market. Despite extensive research, the exact mechanisms underlying TN remain elusive. This ambiguity complicates the development of targeted therapies, as treatment approaches often rely on a comprehensive understanding of disease mechanisms.

Without a clear understanding of the root cause or contributing factors, researchers face challenges in identifying novel drug targets or developing innovative treatment strategies. Moreover, the heterogeneity of TN presentations further complicates efforts to elucidate its pathophysiology, leading to variations in treatment response among patients. Thus, such factors restrict the market growth.

Global Trigeminal Neuralgia (TN) Treatment Market Opportunities

Growing Awareness about Trigeminal Neuralgia (TN) 

The growing awareness about Trigeminal Neuralgia (TN) encompasses increased recognition among healthcare professionals and the public about this debilitating condition. More individuals are diagnosed earlier through educational initiatives, medical conferences, and awareness campaigns, leading to greater demand for effective treatments. Research organizations, including the Trigeminal Neuralgia Association, the National Organization for Rare Disorders (NORD), the American Chronic Pain Association, the Facial Pain Association (FPA), the Brain & Life Organization, and the National Institute of Neurological Disorders and Stroke, are investigating the underlying mechanisms of chronic pain and trigeminal neuralgia.

Moreover, they are also developing innovative diagnostic techniques and treatments to raise awareness about these conditions. The Facial Pain Research Foundation and Intl Trigeminal Neuralgia and Me (TNnME) collaborate to coordinate the International Trigeminal Neuralgia Awareness Day on October 7 annually to increase public knowledge and understanding of this ailment. In addition, the European Association of Neurological Societies and the American Academy of Neurology established a collaborative task group to develop comprehensive guidelines for treating TN. Such initiatives for raising disease awareness are anticipated to create opportunities for global market growth.

Regional Analysis

Based on region, the global trigeminal neuralgia (TN) treatment market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Market

North America is the most significant global trigeminal neuralgia (TN) treatment market shareholder and is expected to expand substantially during the forecast period. The increasing incidence of TN and the flourishing geriatric population contribute to the North American trigeminal neuralgia treatment market. According to the NORD (National Organization for Rare Disease), around 10,000-15,000 new cases of TN are reported annually in the United States. Moreover, projections indicate that the population of Americans aged 65 and over will rise to 95 million by 2060, a significant growth compared to the 52 million estimated in 2018. The regional market development is driven by increasing awareness regarding early diagnosis and treatment of rare neurological illnesses, favorable reimbursement policies, and advancements in research and development.

Moreover, the widespread availability of healthcare services and the significant amount of money spent on healthcare in the United States and Canada also contribute to the growth of the market for trigeminal neuralgia treatment. These countries have many pharmaceutical firms involved in researching and developing new pharmaceuticals for the treatment of trigeminal neuralgia, which is driving advancements in the field.

Furthermore, the anticipated approval of promising pharmaceutical candidates in the upcoming years will boost the regional market. For instance, in October 2022, the Food and Drug Administration (FDA) gave Fast Track designation to basimglurant (NOE-101) for treating pain related to trigeminal neuralgia. Basimglurant is a powerful substance that blocks the activity of metabotropic glutamate receptor 5 (mGluR5), which is excessively produced in cases of chronic pain. The company is now assessing the effectiveness and safety of basimglurant in adults experiencing pain related to trigeminal neuralgia. This is done through a prospective, double-blind, randomized-withdrawal, placebo-controlled phase 2/3 trial.

In Asia-Pacific, the demand for treatment alternatives is expected to rise significantly in the near future due to the high prevalence of TN. According to a survey conducted by Omics International, about 4,458,090 individuals in China are affected by TN, which accounts for 2.6% of the entire population. The presence of significant medical demands that have not been satisfied, along with rapidly growing research and development investments in healthcare and increasing healthcare expenditures in developing nations like India and China, create opportunities for market participants in the trigeminal neuralgia care market.

Furthermore, the number of innovative medications approved for the treatment of TN has increased. For instance, in December 2021, Accuray obtained approval from the Japanese Ministry of Health, Labor and Welfare (Shonin) to commercially sell the CyberKnife robotic radiosurgery system in Japan to treat trigeminal neuralgia (TN). The approach is presently employed for treating TN in the United States, EIMEA (Europe, India, the Middle East, and Africa), and other global regions. According to a press statement from Accuray, the latest clearance of Shonin would allow more TN patients to receive a high-precision radiosurgery treatment, usually administered in a single outpatient session. Consequently, these factors are estimated to boost the regional market expansion.

Segmental Analysis

The global trigeminal neuralgia (TN) treatment market is segmented by treatment type and treatment providers.

Based on treatment type, the global trigeminal neuralgia (TN) treatment market is divided into drugs and surgeries.

Drugs are used as a primary treatment for trigeminal neuralgia (TN). There are various drugs like Carbamazepine, oxcarbazepine, and others. Carbamazepine is a frontline medication for treating Trigeminal Neuralgia (TN), a debilitating facial pain condition. It operates by stabilizing overactive nerve cells responsible for transmitting pain signals. Carbamazepine effectively reduces the frequency and intensity of TN attacks, offering relief to patients. The medication's mechanism involves blocking sodium channels, inhibiting neurons' hyperexcitability, thereby reducing pain transmission.

Furthermore, it typically takes several days to weeks for Carbamazepine to reach its full therapeutic effect. However, its efficacy can vary among individuals, and careful titration is necessary to balance effectiveness against potential side effects like dizziness, drowsiness, and liver abnormalities. Moreover, Carbamazepine may interact with other medications, requiring close supervision by healthcare professionals. Thus, Carbamazepine plays a crucial role in alleviating the debilitating pain associated with TN, improving patients' quality of life.

Based on treatment providers, the global trigeminal neuralgia (TN) treatment market is divided into hospitals and clinics, ambulatory surgery centers, and others.

Hospitals are prominent primary care providers for various health conditions due to the availability of modern treatment choices, experience in neuropathic pain, favorable payment policies, and increasing healthcare infrastructure. Hospitals provide several therapeutic options for pain management, such as microvascular decompression, stereotactic radiosurgery, rhizotomy, and medicine. The segment's major share is influenced by factors such as high patient turnover, frequent readmissions, and huge operation volumes. Moreover, adopting early detection, acceptance, and efficient management of neurological conditions using less intrusive methods would generate prospects for the growth of the hospital segment.

Recent Developments

• March 2024- IFM Therapeutics announced that Novartis has chosen to exercise its option to acquire all of the remaining shares of IFM Due, a subsidiary of IFM.
• March 2023- Noema Pharma, a biotech firm based in Switzerland focused on treating severe central nervous system (CNS) problems, completed a Series B financing round. The business raised CHF 103 million (USD 112 million) from both new and current investors, surpassing the expected amount. Noema Pharma will use the funds to further develop its clinical-stage assets, specifically its main product, basimglurant (NOE-101). Basimglurant is an inhibitor of mGluR5 and is currently undergoing phase 2b clinical studies for the treatment of severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC).